Clinical trials: Glomerulonephritis
Idiopathic Membranous Nephropathy
MEmbranous Nephropathy Trial Of Rituximab
The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.
- Trial name
- MENTOR (NCT01180036)
- Testing
- Rituximab, Cyclosporine
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Membranous Nephropathy
Omics of Rituximab-resistance
The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict response to RTX, ultimately…
- Trial name
- CONFUCIUS (NCT07416942)
- Testing
- Multi-omics Analysis, Sample collection
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Lupus Nephritis
A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis
This study will compare the efficacy of CellCept [0.5-2 grams per day (g/day) orally (p.o.)] and cyclophosphamide [0.5-1 grams per square meter (g/m2) quarterly] as maintenance treatment for patients with lupus nephritis.
- Trial name
- NCT02081183
- Testing
- Mycophenolate mofetil (MMF), Cyclophosphamide, Maintenance Phase, Cyclophosphamide, Induction Phase
- Where
- 2 sites in Venezuela
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
IgA Nephropathy
Rituximab and RASi in Patients with IgAN
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
- Trial name
- RITA (NCT04525729)
- Testing
- Rituximab, RAS 2410
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Nan Chen,MD
C3 Glomerulopathy, C3 Glomerulonephritis
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant…
- Conditions
- C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
- Trial name
- NCT03369236
- Testing
- Danicopan
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Glomerulonephritis Acute
Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated Glomerulonephritis
Urinary CD4+ and CD8+ T lymphocytes may predict renal flares in patients with inactive ANCA-associated vasculitis and thus serve as early non-invasive biomarkers.
- Trial name
- PRE-FLARED (NCT04428398)
- Testing
- Analysis of urine samples with flow cytometry
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Lupus Nephritis
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.
- Trial name
- NCT06785519
- Testing
- CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- He Huang
IgA Nephropathy, Proteinuria
Acthar on Proteinuria in IgA Nephropathy Patients
IgA nephropathy occurs when IgA-a protein that helps the body fight infections-settles in the kidneys. IgA deposits may cause the kidneys to leak blood and sometimes protein in the urine.
- Trial name
- NCT02382523
- Testing
- Acthar 80 unit injection
- Where
- United States
- Sponsor
- Baylor College of Medicine
IgA Nephropathy
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
-IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease.
- Trial name
- NCT02231125
- Testing
- Losartan, Abelmoschus manihot
- Where
- 88 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Chen Xiangmei
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid…
- Trial name
- NCT05441826
- Testing
- VB119
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tenet Medicines
Mycophenolate Mofetil, Cyclophosphamide
MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN
A prospective, randomized, multicenter, open-label, parallel-arm Study to compare effectiveness of mycophenolate mofetil versus cyclophosphamide in the Induction Therapy of pediatric patients with Active Proliferative Lupus…
- Conditions
- Mycophenolate Mofetil, Cyclophosphamide, Lupus Nephritis
- Trial name
- MyCITS (NCT05495893)
- Testing
- Cyclophosphamide, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Second Xiangya Hospital of Central South University
Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
Telitacicept for PGNMID: A Single-Arm Study
This single-center, prospective, single-arm study will evaluate the efficacy and safety of telitacicept in 10 adults with biopsy-proven proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
- Trial name
- NCT07111338
- Testing
- Telitacicept 160mg
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital
Focal Segmental Glomerulosclerosis (FSGS)
Rituximab Treatment of Focal Segmental Glomerulosclerosis
The purpose of this study is to determine whether the approved drug, rituximab, is effective in the treatment of focal segmental glomerulosclerosis (FSGS)
- Trial name
- NCT00550342
- Testing
- rituximab
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lupus Nephritis
A Study of Telitacicept in Lupus Nephritis
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
- Trial name
- NCT05680480
- Testing
- Telitacicept 240 mg, Telitacicept 160 mg
- Where
- 45 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Focal Segmental Glomerulosclerosis
AMPK-activation by Metformin in FSGS: AMP-FSGS
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal…
- Trial name
- AMP-FSGS (NCT06090227)
- Testing
- Metformin + Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Diabetic Nephropathies, Lupus Nephritis
Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease
During 1993 and 2006, a total of 987 patients older than 20 years underwent native kidney biopsy at the Renal Division of this hospital.
- Conditions
- Diabetic Nephropathies, Lupus Nephritis, Rapidly Progressive Glomerulonephritis, Chronic Kidney Diseases
- Trial name
- NCT03201406
- Where
- 2 sites in Taiwan
- Volunteers
- 837 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection
This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for…
- Trial name
- NCT05320133
- Testing
- JWC containing quadruple therapy, Bismuth-containing quadruple therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Glomerulonephritis, Membranous
Rituximab in Refractory Primary Membranous Nephropathy
Primary membranous nephropathy (PMN), an autoimmune disease mostly associated with anti-phospholipase-A2-receptor (PLA2R) antibodies, is one of the most common causes of nephrotic syndrome in adults.
- Trial name
- NCT03880643
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Istanbul University